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Cardiovascular risk is associated with cognitive decline and this effect is attributed to brain 
pathology including white matter hyperintensity (WMH) burden. Low dose aspirin is 
frequently recommended for reducing vascular events. We aimed to investigate the effect of 
taking aspirin on the association between cardiovascular risk, WMH burden and cognitive 
function. 
Study design 
The study sample was drawn from 318 dementia free adults aged 67-71 years. Brain 
Magnetic Resonance Imaging (MRI) scans were acquired from 239 participants. 
Main outcome measures 
WMH total lesion volumes (TLV) were extracted using the automated lesion segmentation 
algorithm. We measured cardiovascular risk by calculating ASSIGN score. Cognitive ability 
was measured using a processing speed test. We developed structural equation models to test 
our hypothesis. 
Results 
Taking aspirin was reported by 68 participants (47.1% male, mean age=68.8 years). The 
demographic measures did not differ significantly by aspirin use. In aspirin users, there was a 
strong negative association between WMH TLV and cognition (β = -0.43, p-value < 0.001) 
while in non-users of aspirin, the only significant predictor of poorer cognition was 




Aspirin use moderates the negative effect of WMH burden on cognition. Considering WMH 
burden in addition to cardiovascular risk could improve the prediction of cognitive decline in 
older adults with aspirin use. 






Low dose aspirin reduces the frequency of adverse vascular events in those at increased risk 
of occlusive cardiovascular disease (CVD). People who benefit include those: with a history 
of myocardial infarction, ischaemic stroke, unstable or stable angina, peripheral 
arterial disease, or atrial fibrillation (1). The pathophysiology of CVD risk contributes to 
cognitive decline through multiple pathways that include cerebral hypo-perfusion, hypoxia, 
hippocampal atrophy, emboli, or infarcts (2, 3). However, the value of aspirin use in 
prevention of cognitive impairment remains uncertain since results relating to the influence of 
taking aspirin on cognitive function are inconsistent (4-6). 
Brain Magnetic Resonance Imaging (MRI) detected white matter hyperintensities (WMH) 
provide a biomarker of cardiovascular and cerebrovascular disease and are a ubiquitous 
imaging finding in older adults (7, 8). The relationship between WMH and cognitive decline 
is well-documented (9, 10), making WMH a potential factor in the pathway through which 
aspirin could affect cognition in older people. Few studies examine a possible association 
between aspirin use and MRI markers of cerebrovascular disease (11, 12). Although one 
study reported that there was no clinically significant effect of long-term aspirin use on 
WMH volume in women (13), the study was carried out in older women over 75y and did not 
examine the effect of aspirin on dementia-related pathology or on cognition. 
Among all cognitive domains, information processing speed seems to be more affected by 
WMH burden due to injury or disease and ageing (14, 15). The Rotterdam Scan study 
showed a significant association between white matter lesion progression and reduced 
information processing speed (16). Similarly in a non-demented elderly population the 
increased periventricular WMH volume was associated with reduced cognitive speed, but not 
with memory (17). The Digit Symbol (DS) test is a widely-used and standardized 
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psychometric test with high re-test reliability that evaluates the performance of cognitive 
processes including visual analysis, focused attention, response selection and motor 
operations fluently under time pressure (18). Because of its psychometric properties, the DS 
test was adopted as the measure of information processing speed for this research. 
1.2.Aims  
Against this background, we aim to (i) assess the relationship between CVD risk factors, 
WMH total lesion volume (TLV) and processing speed measured by DS test, and (ii) 
investigate the effect of aspirin use on possible associations observed here.  
2. METHODS 
2.1.Study design and participants 
Participants were volunteers recruited to a longitudinal observational study of people born in 
1936, the Aberdeen 1936 Birth Cohort (ABC1936). The mental ability of all participants was 
estimated using a cognitive test (The Moray House Test, MHT) at age 11±0.5y as part of 
Scottish Mental Survey of 1947 (SMS 47). With the approval of the NHS Local Research 
Ethics Committee (reference 03/0151- abc1936), 498 survivors of SMS 47 aged between 63y 
to 67y were recruited into ABC1936 though 1999-2002. Full details of ABC1936 are 
described elsewhere (19). For this study purpose we used data from wave three of ABC1936 
controlling for childhood factors. Cognitive performance, general health parameters and MRI 
brain exams were completed satisfactorily at age 68y as part of the third assessment and have 
been used in this study. A fellow chart summarising how the sample was recruited for the 
ABC1936 study is shown in Fig. 1.  
2.2.Aspirin use and cardiovascular risk score  
Participants were asked about their current medications at the baseline and all waves of 
examination. Aspirin use was based on self-reported aspirin administration. CVD risk was 
measured using the ASSIGN score. ASSIGN was developed in the Scottish Heart Health 
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Extended Cohort, aiming to target social gradients in predicting cardiovascular outcome (20). 
We used age, sex, adulthood socioeconomic status (SES), family history of coronary heart 
disease or stroke, history of diabetes and rheumatoid arthritis, number of cigarettes smoked 
daily, systolic blood pressure, total cholesterol and HDL cholesterol to calculate ASSIGN 
(Version 1.5.1, http://www.assign-score.com/estimate-the-risk/). Scottish Index of Multiple 
Deprivation (SIMD) obtained through participants’ postcode was used as an estimate of adult 
SES and was considered as a CVD risk factor in ASSIGN calculation.  
2.3.Brain MRI scans and image analysis 
Brain MRI exams were obtained using a 1.5 T ( NVi GE system, Milwaukee, WI) scanner 
with T2 axial (TR/TE 4,900/81.4, slice thickness 5 mm, space 1.2 mm), fluid attenuation 
inversion recovery axial (FLAIR) (TR/TE 9,002/1.33, TI 2,200, slice thickness 5mm, space 
1.2mm) and 3D T1-weighted (TR/TE 20/6ms, flip angle 35°, slice thickness 1.6 mm, matrix 
256 × 192, in-plane resolution 1 × 1mm) sequences (21).  
White matter total lesion volume (WMH TLV) was obtained using the Lesion Growth 
Algorithm provided by the open-source Lesion Segmentation Toolbox (https://www.applied-
statistics.de/lst.html). This fully-automated lesion segmentation algorithm separates brain 
tissue classes (white matter, grey matter, cerebrospinal fluid) using a T1 image, then utilises 
the FLAIR image to detect and classify hyperintense (bright) voxels, providing a lesion 
prediction map, total lesion number, and TLV. Further information about this segmentation 
approach can be found elsewhere (22). 
2.4.Cognition and education 
Processing speed was measured using the Digit Symbol (DS) test (18). DS scores were 
transformed to an IQ-type score (mean =100, standard deviation = 15).The highest 
educational qualification attained was coded from “none” as 1, lower and higher leaving 
certificate coded 2 and 3, Scottish vocational certificate coded 4; ordinary grades coded 5; 
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Higher / Advanced level were coded 6; undergraduate and postgraduate degrees coded 7 and 
8 respectively, up to “professional or higher degree” levels coded as 9 (19).   
 2.5. Statistical analyses  
The distribution of data was explored visually and by skewness test. The two groups were 
compared using Chi-Square test for categorical variables, the Mann-Whitney U tests for not 
normally distributed outcomes and the Independent-Sample t test for normally distributed 
outcomes. 
Structural Equation Models (SEMs) were developed with WMH TLV, ASSIGN and the 
standardised DS score. ASSIGN was assumed to have a direct and an indirect effect on 
cognition. The indirect effect of ASSIGN on cognition was hypothesised to be through its 
effects on WMH TLV. We also hypothesised that WMH TLV would have a direct effect on 
cognitive function. We adjusted SEMs for the confounding effect of age, gender, childhood 
IQ and education on late life cognition. The goodness of fit was assessed according to the 
combined value of Comparative Fit Index (CFI) ≥ 0.95 and Root Mean Square Error of 
Approximation (RMSEA) ≤ 0.06 as an acceptable fit of the model to the data (23). All 
analyses were carried out using IBM SPSS v24 and p value <0.05 was considered as 
significant. 
3. RESULTS 
3.1. Characteristics  
The study sample was drawn from 318 dementia free adults aged 67-71y (Table 1). The 
demographic measures did not differ significantly by aspirin use. Aspirin users were more 
likely to be taking anti-hypertensive medication and statins, and to have a history of cardio- 
and cerebrovascular events and diabetes. No significant difference was observed between 
groups by DS, ASSIGN or WMH TLV.   
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3.2. SEMs results; ASSIGN, WMH, cognition and the moderating effect of aspirin 
Fig.2 shows a brain MRI scan of a subject with WMH (A) and same slice with lesion map 
overlaid (B). 
Results of the SEM for all participants and for aspirin vs no aspirin group are shown in Fig.3 
and Fig.4 These models are adjusted for confounders including age, gender, childhood IQ, 
and education (Fig.3). 
In all participants (Fig. 3), ASSIGN was associated with poorer cognition (β= -0.17, p-value 
<0.001). In addition, we found a direct independent negative effect of WMH TLV on 
cognition (β= -0.12, p-value =0.038). The negative effect of ASSIGN on cognition was not 
mediated through WMH TLV (β = 0.04, p-value= 0.478). Model fit indices (CFI =0.98 
RMSEA =0.03) indicated a very good fit of the model to the data.  
We then performed a multiple group comparison to control for these relationships in aspirin 
use (Fig.4a and 4b). For simplicity confounders are not shown here. Among those who do not 
report aspirin use there is a significant association between ASSIGN and cognition (β= -0.17, 
p-value =0.001) and the association betweenWMH TLV and cognition was not significant. 
Among aspirin users, WMH TLV significantly affected cognitive function with β = -0.43, p-
value <0.001, the effect of ASSIGN on cognition is not significant. We controlled the model 
for factors that are different between aspirin use and no use, taking anti-hypertensive 
medication and statins, and a history of cardio- and cerebrovascular events, and it did not 
change the results. Differences in the standardised regression weights in models of aspirin use 
and non-use were assessed by examining the critical ratio of estimated parameters. The effect 




As seen in table 1, 50.7 % of aspirin use group had a history of cardio- and cerebrovascular 
events. We developed a similar path diagram for the association of ASSIGN, WMH and DS 
score and performed a multiple group comparison for the presence and absence of history of 
cardio- and cerebrovascular events. In those with no history of events, ASSIGN was 
significantly associated with poorer cognitive function (β= -0.21, p-value <0.001) but in 
existence of a history of event, WMH was the only significant predictor of cognitive decline 
(β= -0.52, p-value <0.001). These results were comparable to our hypothesized model for 
aspirin. 
4. DISCUSSION 
4.1. Interpretation of results 
This study shows that aspirin use exacerbates the negative effect of WMH burden on 
information processing speed. This may be because aspirin treatment and brain lesion burden 
share a common cause, such as a history of stroke or myocardial infarction that are not 
included in ASSIGN. Our results show that the underlying mechanism for cognitive decline, 
with a focus on information processing speed, could be different in older adults with aspirin 
consumption.  
Low dose aspirin conveys substantial benefit for secondary prevention of recurrent events in 
patients who have suffered cardio- and cerebrovascular events such as MI or stroke (24), but 
the existing evidence cannot support an advantage of aspirin use in the prevention or 
treatment of age-related cognitive decline. 
In preliminary analyses in ABC1936 of an association between CVD risk factors and brain 
lesions associated with cerebrovascular disease we observed significant links between CVD 
risk and WML’s (21, 25). In this analysis using more informative statistical models than 
previously available, we do not find an association between ASSIGN and WMH TLV. This 
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may be due to ASSIGN not incorporating diastolic BP, which has been shown to influence 
the severity of WMH burden (25). It may also be the case that measures of cardiovascular 
risk taken in mid-life are more reflective of WMH burden in late-life (26), whereas here we 
measured cardiovascular risk in older adults.  
There are alternate plausible explanations for the association between ASSIGN and cognitive 
function already suggested in several studies. These alternatives, for example, include a role 
for brain microvascular changes following hyperglycaemia, enhanced amyloid β degradation 
following insulin resistance in diabetic patients (27), the effect of hypertension on vascular 
structure of the brain (28) and inflammation associated with smoking (29). Future studies 
could clarify the association of ASSIGN and poorer information processing we found here. 
Many studies have evaluated the effect of taking aspirin on cognitive function or dementia 
but the effect of aspirin on the biomarker of subclinical cerebrovascular health has only been 
investigated in a small number of studies with inconsistent results (12, 13). There has been 
increasing interest to explore this relationship. Holcomb et al reported no significant 
association between chronic aspirin use and WMH volume in women. Their study consisted 
of a large sample (n=1193) of older adults, however, only including women participants with 
the average age of 77 years at MRI examination (13). The ongoing ASPREE-NEURO study 
aims to investigate the effect of aspirin on cerebral micro-bleeds and WMH but is yet to 
report (30).  
The results of our SEM analyses reveal a negative association of WMH volume and cognition 
among aspirin users. Our results might represent related bases for taking aspirin and brain 
lesion burden that are not included in ASSIGN such as a history of stroke or myocardial 
infarction. As the comparison of the path diagram in people with and without history of 
cardio- and cerebrovascular events showed similar results to our model. This could be further 
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investigated in a larger sample by comparing aspirin usage in people with and without a 
history of cardio and cerebrovascular events. It also demonstrates that underlying pathways 
towards cognitive decline could be different in older adults’ aspirin users.  
These results show that inclusion of WMH volume in addition to the CVD risks built in 
ASSIGN score could improve the prediction of cognitive decline in older adults who take 
aspirin. For example, it may be beneficial to include categories of WMH burden (mild, 
moderate, and severe). However, as volumetric analysis of WMH burden is a relatively recent 
method and the pathogenesis of WMH remains unclear, further research is required to 
determine appropriate thresholds of WMH burden to create mild/moderate/severe categories. 
4.2. Strength and weakness  
To our knowledge, this is the first study to evaluate the effect of WMH volume on cognition, 
whilst simultaneously examining the moderating effect of taking aspirin on this association. 
This study benefits from availability of a life course model considering wide ranges of 
covariates and predictors for cognitive function and WMH burden. Uniquely, we were able to 
account for childhood IQ as strong predictor of cognitive ability in late life. We were also 
able to account for composite cardiovascular risk using ASSIGN score which is relevant to 
the population studied.  
Self-reported medications and disorders might introduce recall bias. However, the 
participants included in this study were dementia free which would attenuate the likelihood of 
misclassification or under/over-estimation of the self-reported variables and the results. Cross 
sectional analysis of WMH is insufficient to explain the causal relationship for the difference 
between aspirin users and non-users observed in this study. There are other potential 
confounders that could influence the association reported in this study which were not 
included in our model such as exercise and diastolic blood pressure. ASSIGN score used to 
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estimate cardiovascular risk factor in this study is not representing current cardiovascular 
disease which could be potential confounders in our model. 
4.3.Future research 
Future studies should take into account of changes in prescribing perhaps captured through 
routinely recorded pharmacy prescribing information to adequately account for effect of 
aspirin and other cardiovascular related medications on this relationship. Longitudinal MRI 
data analysis could potentially enable researchers to examine whether effects of taking aspirin 
on the brain are causal after controlling for the effects of potential confounders.  
5. CONCLUSION 
Aspirin use moderates the negative effect of WMH volume on cognition. This probably 
represents the same case made for taking aspirin and brain lesion burden such as history of 
cardiovascular events that are not included in ASSIGN score. The underlying pathways 
towards cognitive decline may differ among older aspirin users.  
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Table 1. Participants’ characteristics. (The two groups were compared using Chi-Square test, 
Mann-Whitney or Independent-Sample t test where appropriate).  





Demographic     
No of male (%) 118(47.2) 32(47.1) 0.547 
Childhood IQ 101.9(13.1) 102. (14.7) 0.814 
Age Mean [y](SD) 68.7(0.8) 68.8(0.7) 0.187 
Education Mean(SD) 3.3(2.2) 3.4(2.3) 0.658 
Body Mass Index Mean(SD) 27.2(4.6) 27.4(4.1) 0.361 
Medications    
Statins yes (%)  36(14.4) 41(60.3) <0.001 
No of anti-hypertensive, yes (%)  88(35.2) 47(69.1) <0.001 
Cardiovascular risk    
No of smoking None (%) 116(47.9) 31(45.5) 
0.054 No of smoking Ex (%) 88(36.4) 33(48.5) 
No of smoking Current (%)  38(15.7) 4(5.9) 
Systolic BP 137.9(16.8) 135.0(17.8) 0.229 
Diastolic BP 78.2(8.7) 76.1(9.8) 0.083 
HDL cholesterol 1.5(0.3) 1.4(0.4) 0.381 
Total cholesterol 5.7(0.9) 5.4(1.0) 0.031 
Diabetes yes (%) 20(8.1) 12(17.2) 0.038 
Family history of CVD yes (%) 179(74.2) 50(76.9) 0.748 
SIMD 15.1(12.4) 14.7(11.7) 0.853 
ASSIGN score 28.9(11.8) 29.6(13.3) 0.642 
Cardio- & cerebrovascular event yes (%) 15(6.1) 34(50.7) <0.001 
Cognitive ability tests, Mean(SD)    
Standardised Digit Symbol  100.4(14.8) 98.4(15.8) 0.575 
Total lesion volume (ml) (n=190:49) 4.1(5.5) 5.2(8.4) 0.267 


















Fig. 2.  Brain MRI scan of a subject shows white matter hyperintensity burden in fluid 
attenuation inversion recovery axial (FLAIR). (A) 3D T1-weighted MR image with white 
matter lesions and (B) automated segmentation of the white matter hyperintensity burden (in 




Fig. 3.  Path diagram of overall hypothesised model (n=241), bold standardised regression 
weights represents in the diagram are statistically significant (p< 0.05). r1 and r2 are 
residuals. cIQ; childhood IQ, Edu; Education. 
 
 
Fig. 4. Path diagrams for multiple group comparison between (a) no aspirin use (n=190) and 
(b) aspirin use (n=49) in the overall hypothesised model, confounders are not shown for 
simplicity, bold standardised regression weights represents in the diagram are statistically 
significant (p< 0.05). r1 and r2 are residuals. 
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